Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Barr Pharmaceuticals has reported that the US District Court of New Jersey has ruled in favor of its subsidiary, Barr Laboratories, in the challenge of the patent listed by Bayer Schering Pharma, in connection with Bayer Schering's Yasmin oral contraceptive.
Subscribe to our email newsletter
In this ruling, the Court found that the patent at issue was invalid, because it was obvious. Yasmin (drospirenone and ethinyl estradiol) provides an oral contraceptive regimen consisting of 21 active tablets each containing 3mg of drospirenone and 0.03mg of ethinyl estradiol and seven inert tablets. Yasmin is indicated for the prevention of pregnancy in women who elect to use an oral contraceptive.
Bruce Downey, chairman and CEO of Barr, said: “We are delighted that Judge Sheridan has invalidated the patent on Yasmin. We are currently reviewing the opinion in the case and evaluating all of our options.”